Table 1.
Cytotoxities and anti-HIV activities of YNS-PY-F. CC50 is the concentration that inhibits 50% of cell viability. EC50 is the effective concentration that inhibits 50% of viral production or enzyme activity.
| Samples | Cells | HIV strains/enzyme | Assay | CC50 (μg/mL) | EC50 (μg/mL) | SI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YNS-PY-F | C8166 | HIV-1IIIB | CPE | 438.73 | 0.96 | 457.01 | ||||||
| p24 | 3.98 | 110.23 | ||||||||||
| HIV-1RF | CPE | 1.53 | 286.75 | |||||||||
| p24 | 9.48 | 46.28 | ||||||||||
| HIV-1A17 | CPE | 0.88 | 498.56 | |||||||||
| p24 | 4.04 | 108.60 | ||||||||||
| HIV-1AO18 | CPE | 7.20 | 60.93 | |||||||||
| p24 | 9.79 | 44.81 | ||||||||||
| HIV-2ROD | CPE | 6.17 | 71.11 | |||||||||
| H9/HIV-1IIIB | CPE | 7.60 | 57.73 | |||||||||
| MT-4 | HIV-1IIIB | MTT | 922.47 | 2.22 | 415.53 | |||||||
| — | RT | ELISA | — | 4.60 | — | |||||||
| AZT | C8166 | HIV-1IIIB | CPE | 1120.84 | 1.30 a | 862,184.62 | ||||||
| p24 | 1.94 a | 577,752.58 | ||||||||||
| HIV-1RF | CPE | 2.95 a | 379,945.76 | |||||||||
| p24 | 6.48 a | 172,969.14 | ||||||||||
| HIV-1A17 | CPE | 4.22 a | 265,601.90 | |||||||||
| p24 | 4.11 a | 272,710.46 | ||||||||||
| HIV-2ROD | CPE | 3.07 a | 365,094.46 | |||||||||
| MT-4 | HIV-1IIIB | MTT | 358.50 | 0.85 a | 421,764.71 | |||||||
| NVP | C8166 | HIV-1AO18 | CPE | — | 61.70 b | — | ||||||
| p24 | — | 42.11 b | — | |||||||||
| T20 | C8166 | H9/HIV-1IIIB | CPE | — | 14.96 a | — | ||||||
| PFA | — | RT | ELISA | — | 1.03 | — | ||||||
SI (selective index) = CC50/EC50. CPE: cytopathic effect. a: ng/mL. b: pM. The data shown in the table are means of at least two independent experiments.